Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
IL1B 3553 RILONACEPT CHEMBL1201830 inhibitor, binder ChemblInteractions, DrugBank, TTD 23319019, 23553601
IL1B 3553 GALLIUM NITRATE CHEMBL1200983 antagonist, inhibitor DrugBank, TTD 16122880
IL1B 3553 VX-702 CHEMBL1090090 DrugBank
IL1B 3553 GEVOKIZUMAB CHEMBL1743026 TdgClinicalTrial, ChemblInteractions, DrugBank
IL1B 3553 MAFOSFAMIDE CHEMBL59990 NCI 3497116
IL1B 3553 TALMAPIMOD CHEMBL514201 DrugBank
IL1B 3553 MELATONIN CHEMBL45 NCI 8077674
IL1B 3553 DIACEREIN CHEMBL41286 TdgClinicalTrial
IL1B 3553 AMG-108 CHEMBL2109458 antibody TTD
IL1B 3553 IBUDILAST CHEMBL19449 inhibitor DrugBank, TTD
IL1B 3553 BELNACASAN CHEMBL2107819 DrugBank
IL1B 3553 ACITRETIN CHEMBL1131 NCI 1431212, 2954576
IL1B 3553 BECLOMETHASONE DIPROPIONATE CHEMBL1200500 NCI 9176529
IL1B 3553 NICARDIPINE CHEMBL1484 NCI 1888883
IL1B 3553 PENTOXIFYLLINE CHEMBL628 NCI 8048000
IL1B 3553 CLODRONATE DISODIUM CHEMBL1520188 PharmGKB
IL1B 3553 MEDRONIC ACID CHEMBL180570 PharmGKB
IL1B 3553 PHORBOL MYRISTATE ACETATE CHEMBL279115 NCI 8615653
IL1B 3553 ETIPREDNOL DICLOACETATE CHEMBL2107614 DrugBank
IL1B 3553 FLUTICASONE PROPIONATE CHEMBL1473 NCI 11943316
IL1B 3553 LITHIUM CHEMBL2146126 NCI 9342951
IL1B 3553 PENTAMIDINE CHEMBL55 NCI 8370344
IL1B 3553 CELASTROL CHEMBL301982 TTD
IL1B 3553 SODIUM beta-NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE CHEMBL295069 NCI 8724378
IL1B 3553 CEFACLOR CHEMBL680 NCI 3260587
IL1B 3553 RESVERATROL CHEMBL165 NCI 16389574
IL1B 3553 CYTARABINE CHEMBL803 NCI 7523795
IL1B 3553 HYDROQUINONE CHEMBL537 NCI 7589278
IL1B 3553 RALOXIFENE CHEMBL81 NCI 12773123
IL1B 3553 VERAPAMIL CHEMBL6966 NCI 2686646
IL1B 3553 CANAKINUMAB CHEMBL1201834 inhibitor, binder, antibody MyCancerGenome, TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 19169963
IL1B 3553 ERYTHROMYCIN CHEMBL532 NCI 2534682
IL1B 3553 OFLOXACIN CHEMBL4 NCI 3260587
IL1B 3553 NIMUSTINE HYDROCHLORIDE CHEMBL1256616 NCI 1331350, 2350191
IL1B 3553 HYDROCORTISONE CHEMBL389621 NCI 2162889
IL1B 3553 LANSOPRAZOLE CHEMBL480 NCI 16815316
IL1B 3553 THYROGLOBULIN CHEMBL1201650 NCI 2788696

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
IL1B rs16944 GG lansoprazole efficacy no No significant difference in the percent of patients who failed Helicobacter pylori (H. pylori) treatment were seen between the two genotype groups. Patients also received amoxicillin and clarithromycin. Please note alleles have been complemented to the plus chromosomal strand. Genotype GG is not associated with response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to genotypes AA + AG. 14638340 1183679914
IL1B rs16944 AG lansoprazole efficacy yes Patients with the AG genotype had a decreased likelihood of Helicobacter pylori (H. pylori) eradication failure, as compared to those with the GG genotype. Patients were also given amoxicillin and clarithromycin, and were treated for 1 week. Please note alleles have been complemented to the plus chromosomal strand. Genotype AG is associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to genotype GG. 16815316 1183680034
IL1B rs16944 AA lansoprazole efficacy yes Patients with the AA genotype had a decreased likelihood of Helicobacter pylori (H. pylori) eradication failure, as compared to those with the GG genotype. Patients were also given amoxicillin and clarithromycin, and were treated for 1 week. Please note alleles have been complemented to the plus chromosomal strand. Genotype AA is associated with increased response to lansoprazole, omeprazole or rabeprazole in people with Helicobacter Infections as compared to genotype GG. 16815316 1183680029
IL1B rs16944 AA omeprazole efficacy no No significant differences in the cure rate of Helicobacter pylori (H. pylori) were seen between any of the genotypes, either in the intent-to-treat or the per-protocol analysis. Patients were also given amoxicillin and clarithromycin, and were treated for 1 week. Please note alleles have been complemented to the plus chromosomal strand. Genotype AA is not associated with response to omeprazole and rabeprazole in people with Helicobacter Infections as compared to genotypes AG + GG. 21054464 1183680131
IL1B rs1143634 GG infliximab efficacy yes Patients with Crohn's Disease and the GG genotype showed significantly higher IL1B serum concentrations and significantly lower responses to infliximab treatment as compared to those with the AA or AG genotype. Patients with ulcerative colitis were also studied, but no association between genotype and IL1B concentrations or response to treatment was seen. Genotype GG is associated with decreased response to infliximab in people with Crohn Disease as compared to genotypes AA + AG. 22960943 1183689654
IL1B rs1143623 CG + GG Tumor necrosis factor alpha efficacy yes Good responders (those with a reduction of >=75% in PASI score after 3 months) were compared against non-responders (those with a reduction of <50% in PASI score after 3 months). Statistical results adjusted for age, gender, psoriatic arthritis and previous treatments and corrected for multiple testing using the false discovery rate. Please note that alleles have been complemented to the plus chromosomal strand. Genotypes CG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors or ustekinumab in people with Psoriasis as compared to genotype CC. 28696418 1449155387
IL1B rs1143634 A morphine "dosage","efficacy" yes There was an interaction between this variant and Chinese or Indian ethnicity in terms of morphine consumption. The opposite association was seen in patients of Malay ethnicity. Allele A is associated with increased dose of morphine in women with Pain, Postoperative as compared to allele G. 27649267 1450373495
IL1B rs1143623 GG metformin efficacy yes as measured by decreased HbA1c. Discovery population (which also received glibenclamide or chinese medicine containing glibenclamide) also saw decreases in waist, hip circumference and BMI. Genotype GG is associated with increased response to metformin in people with Diabetes Mellitus as compared to genotypes CC + CG. 26401715 1447676673
IL1B rs1143627 AG + GG Tumor necrosis factor alpha efficacy yes Good responders (those with a reduction of >=75% in PASI score after 3 months) were compared against non-responders (those with a reduction of <50% in PASI score after 3 months). Statistical results adjusted for age, gender, psoriatic arthritis and previous treatments and corrected for multiple testing using the false discovery rate. Please note that alleles have been complemented to the plus chromosomal strand. Genotypes AG + GG is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors or ustekinumab in people with Psoriasis as compared to genotype AA. 28696418 1449155401
IL1B rs1143634 GG omeprazole efficacy no No significant differences in the cure rate of Helicobacter pylori (H. pylori) were seen between any of the genotypes, either in the intent-to-treat or the per-protocol analysis. Patients were also given amoxicillin and clarithromycin, and were treated for 1 week. Please note alleles have been complemented to the plus chromosomal strand. Genotype GG is not associated with response to omeprazole and rabeprazole in people with Helicobacter Infections as compared to genotypes AA + AG. 21054464 1183680137
IL1B rs1143634 A morphine "dosage","efficacy" yes There was an interaction between this variant and Malay ethnicity in terms of morphine consumption. The opposite association was seen in patients of Chinese or Indian ethnicity. Allele A is associated with decreased dose of morphine in women with Pain, Postoperative as compared to allele G. 27649267 1450373502
IL1B rs4848306 AA + AG Tumor necrosis factor alpha efficacy yes Cohort with inflammatory bowel disease (IBD). Subcohorts with Crohn's disease (CD) and ulcerative colitis (UC) were also analyzed. Significant results for this genotype seen for IBD and UC cohorts. Treatment efficacy was defined using the three-step scale (failure, response, or remission) and reflected the maximum response within 22 weeks after treatment initiation. Genotypes AA + AG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype GG. 24776844 1296666859